JP2020501508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501508A5 JP2020501508A5 JP2019513820A JP2019513820A JP2020501508A5 JP 2020501508 A5 JP2020501508 A5 JP 2020501508A5 JP 2019513820 A JP2019513820 A JP 2019513820A JP 2019513820 A JP2019513820 A JP 2019513820A JP 2020501508 A5 JP2020501508 A5 JP 2020501508A5
- Authority
- JP
- Japan
- Prior art keywords
- multimer
- octamer
- tetramer
- antibody
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 229960002087 pertuzumab Drugs 0.000 claims 2
- 108020001580 protein domains Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 229940119059 actemra Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 239000012459 cleaning agent Substances 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940082789 erbitux Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 229940048921 humira Drugs 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 229940071829 ilaris Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229940076783 lucentis Drugs 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940092597 prolia Drugs 0.000 claims 1
- 229940116176 remicade Drugs 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 229940055944 soliris Drugs 0.000 claims 1
- 229940036185 synagis Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
- 229940079023 tysabri Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 229940055760 yervoy Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022183407A JP2023015311A (ja) | 2016-09-15 | 2022-11-16 | 多量体、四量体および八量体 |
| JP2024209457A JP2025029067A (ja) | 2016-09-15 | 2024-12-02 | 多量体、四量体および八量体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615768.7A GB201615768D0 (en) | 2016-09-15 | 2016-09-15 | Multivalent soluble TCR |
| GB1615768.7 | 2016-09-15 | ||
| GBGB1713342.2A GB201713342D0 (en) | 2017-08-20 | 2017-08-20 | Multimers & tetramers |
| GB1713342.2 | 2017-08-20 | ||
| GB1713351.3 | 2017-08-21 | ||
| GBGB1713351.3A GB201713351D0 (en) | 2017-08-21 | 2017-08-21 | Multimers & tetramers |
| PCT/EP2017/073527 WO2018050902A2 (en) | 2016-09-15 | 2017-09-18 | Multimers, tetramers & octamers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183407A Division JP2023015311A (ja) | 2016-09-15 | 2022-11-16 | 多量体、四量体および八量体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020501508A JP2020501508A (ja) | 2020-01-23 |
| JP2020501508A5 true JP2020501508A5 (enExample) | 2020-11-05 |
Family
ID=60022050
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513820A Pending JP2020501508A (ja) | 2016-09-15 | 2017-09-18 | 多量体、四量体および八量体 |
| JP2022183407A Pending JP2023015311A (ja) | 2016-09-15 | 2022-11-16 | 多量体、四量体および八量体 |
| JP2024209457A Pending JP2025029067A (ja) | 2016-09-15 | 2024-12-02 | 多量体、四量体および八量体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183407A Pending JP2023015311A (ja) | 2016-09-15 | 2022-11-16 | 多量体、四量体および八量体 |
| JP2024209457A Pending JP2025029067A (ja) | 2016-09-15 | 2024-12-02 | 多量体、四量体および八量体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11453726B2 (enExample) |
| EP (1) | EP3512875A2 (enExample) |
| JP (3) | JP2020501508A (enExample) |
| WO (1) | WO2018050902A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3512875A2 (en) * | 2016-09-15 | 2019-07-24 | Quadrucept Bio Limited | Multimers, tetramers&octamers |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2020018715A1 (en) * | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| GB201903767D0 (en) * | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| WO2021190980A1 (en) * | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| CN116096743A (zh) * | 2020-03-22 | 2023-05-09 | 科德路赛普特生物有限公司 | 用于病毒株进化的多聚体 |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| JP2025503704A (ja) * | 2022-01-13 | 2025-02-04 | インゲニア・セラピューティクス・インコーポレイテッド | Ｖｅｇｆ及びｔｉｅ２を結合する融合タンパク質並びにその使用 |
| GB202216503D0 (en) | 2022-11-05 | 2022-12-21 | Quadrucept Bio Ltd | Non-human vertebrates & cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| JPH11508126A (ja) * | 1995-05-23 | 1999-07-21 | モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー | 多量体タンパク質 |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| DE69721548T2 (de) * | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| CA2457636C (en) | 2001-08-10 | 2012-01-03 | Aberdeen University | Antigen binding domains |
| EP1567553A2 (en) * | 2002-12-03 | 2005-08-31 | Avidex Ltd. | Complexes of receptors |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| DE602005011617D1 (de) | 2004-05-19 | 2009-01-22 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| TWI323734B (en) | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| WO2010142551A2 (en) | 2009-06-12 | 2010-12-16 | Ablynx N.V. | Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| AU2010101514A4 (en) | 2009-09-24 | 2014-06-26 | Sprywat Pty Ltd | A Garden Design Method |
| ES2701445T3 (es) * | 2010-10-15 | 2019-02-22 | Leadartis S L | Generación de complejos polipeptídicos multifuncionales y multivalentes mediante el dominio de trimerización del colágeno XVIII |
| CN102924600B (zh) * | 2012-11-14 | 2013-10-30 | 河南大学 | 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用 |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| JP7022993B2 (ja) | 2016-01-11 | 2022-02-21 | インヒブルクス インコーポレイテッド | 多価かつ多重特異性の４１ｂｂ結合融合タンパク質 |
| EP3512875A2 (en) | 2016-09-15 | 2019-07-24 | Quadrucept Bio Limited | Multimers, tetramers&octamers |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
-
2017
- 2017-09-18 EP EP17780319.4A patent/EP3512875A2/en active Pending
- 2017-09-18 WO PCT/EP2017/073527 patent/WO2018050902A2/en not_active Ceased
- 2017-09-18 US US16/333,583 patent/US11453726B2/en active Active
- 2017-09-18 JP JP2019513820A patent/JP2020501508A/ja active Pending
-
2022
- 2022-11-16 JP JP2022183407A patent/JP2023015311A/ja active Pending
-
2024
- 2024-12-02 JP JP2024209457A patent/JP2025029067A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501508A5 (enExample) | ||
| CN112512581B (zh) | 针对cldn18.2和cd3的抗体构建体 | |
| AU2015295239B2 (en) | Antibody constructs for CDH19 and CD3 | |
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| KR102629403B1 (ko) | Vista 항원 결합 분자 | |
| RU2022102624A (ru) | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков | |
| TW201325612A (zh) | 三倍體Ｆｃ融合蛋白及其用途 | |
| MX2023005420A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| JP2018537421A5 (enExample) | ||
| JP2017512063A5 (enExample) | ||
| JP2018529363A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| ES2693370T3 (es) | Politerapia de un anticuerpo CD20 afucosilado con un conjugado de anticuerpo CD22-fármaco | |
| JP2017529067A5 (enExample) | ||
| JP2019508444A5 (enExample) | ||
| JP2013545455A5 (enExample) | ||
| JP2014506132A5 (enExample) | ||
| HRP20210635T1 (hr) | Novi mutant humanog seruma albumina | |
| JP2019504617A5 (enExample) | ||
| JP2020532285A5 (enExample) | ||
| US11773177B2 (en) | Variant antibodies that bind OX40 | |
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
| KR20160138580A (ko) | Wisp1에 결합하는 항원 결합 단백질 | |
| Peerschke et al. | Human blood platelet gC1qR/p33 |